Skip to main content
    I

    Ionis Pharmaceuticals Inc (IONS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $28.01
    -1.05 (-3.61%)

    Market Cap: $4.84B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Ionis Pharmaceuticals Inc (IONS) Earnings: Report Dates and Results

    Updated Nov 9, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Ionis Pharmaceuticals (IONS) is expected to report earnings on Feb 23, 2027. In the quarter ended Sep 30, 2026, Ionis Pharmaceuticals reported EPS of -$0.66, above the -$1.22 estimate. It beat the EPS estimate in each of the last 15 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    78%(31/40)
    Avg Surprise
    +65.78%
    Streak
    15 Q

    Upcoming Estimates

    Reports Feb 23, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$1.50
    Range-$1.71 - -$1.31
    25 analysts
    Revenue Consensus
    $151.85M
    Range$122.46M - $218.30M
    23 analysts
    Reports Apr 27, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.81
    Range-$0.84 - -$0.76
    3 analysts
    EPS Revisions
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago-$1.02+20.9%
    60d ago-$0.83+2.8%
    30d ago-$0.83+2.8%
    7d ago-$0.83+2.8%
    Current-$0.81
    Revenue Consensus
    $244.37M
    Range$147.62M - $337.37M
    7 analysts

    Next Report

    IONS has an expected report date of Feb 23, 2027.

    IONS Earnings Call

    The latest IONS earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, IONS beat 31 and missed 9. Revenue for the quarter ended Sep 30, 2026 was $242.72M, up 54.9% from $156.72M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.66-$1.22N/A+45.90%BeatN/A91 up, 5 downNov 9, 2026$242.72M
    Jun 30, 2026-$0.70-$1.09N/A+35.78%Beat-182.4%6N/AJul 29, 2026$267.95M
    Mar 31, 2026-$0.30-$0.77-$0.96 - -$0.42+61.04%BeatN/A80 up, 2 downApr 29, 2026$246.09M
    Dec 31, 2025-$1.15-$1.33-$1.42 - -$0.99+13.68%BeatN/A70 up, 1 downFeb 25, 2026$203.33M
    Sep 30, 2025-$0.61-$1.05-$1.33 - -$0.88+41.90%BeatN/A81 up, 0 downOct 29, 2025$156.72M
    Jun 30, 2025$0.85$0.16-$0.45 - $0.60+431.25%BeatN/A72 up, 0 downJul 30, 2025$452.05M
    Mar 31, 2025-$0.92-$1.03-$1.35 - -$0.82+10.68%BeatN/A62 up, 0 downApr 30, 2025$131.61M
    Dec 31, 2024-$0.43-$0.84-$1.04 - -$0.70+49.03%BeatN/A91 up, 0 downFeb 19, 2025$226.58M
    Sep 30, 2024-$0.95-$1.16-$1.32 - -$0.94+18.10%BeatN/A173 up, 0 downNov 6, 2024$133.81M
    Jun 30, 2024-$0.24-$0.76-$1.14 - -$0.60+68.42%BeatN/A187 up, 0 downAug 1, 2024$225.25M
    Mar 31, 2024-$0.77-$0.83-$1.38 - -$0.62+7.23%BeatN/A162 up, 2 downMay 7, 2024$119.50M
    Dec 31, 2023-$0.06-$0.83-$1.08 - -$0.28+92.77%BeatN/A172 up, 0 downFeb 21, 2024$324.50M
    Sep 30, 2023-$0.85-$0.89-$1.25 - -$0.74+4.49%BeatN/A161 up, 3 downNov 2, 2023$144.21M
    Jun 30, 2023-$0.41-$0.70N/A+41.43%BeatN/A163 up, 0 downAug 9, 2023$188.41M
    Mar 31, 2023-$0.68-$0.76-$1.43 - -$0.61+10.53%BeatN/A162 up, 0 downMay 3, 2023$130.52M
    Dec 31, 2022-$1.36-$0.92-$1.62 - $0.11-47.83%Miss-196.5%141 up, 1 downFeb 22, 2023$151.89M
    Sep 30, 2022-$0.16-$0.53-$0.94 - -$0.51+69.81%BeatN/A161 up, 0 downNov 9, 2022$159.77M
    Jun 30, 2022-$0.56-$0.47-$0.85 - -$0.32-19.15%MissN/A171 up, 2 downAug 9, 2022$133.79M
    Mar 31, 2022-$0.27-$0.52-$1.19 - -$0.42+48.08%BeatN/A170 up, 0 downMay 4, 2022$141.92M
    Dec 31, 2021$1.41$0.28-$0.29 - $1.68+403.57%Beat+220.5%152 up, 0 downFeb 24, 2022$440.01M
    Sep 30, 2021-$0.34-$0.32-$0.81 - -$0.14-6.25%MissN/A15N/ANov 3, 2021$133.09M
    Jun 30, 2021-$0.26-$0.32-$0.84 - -$0.31+18.75%BeatN/A16N/AAug 4, 2021$125.75M
    Mar 31, 2021-$0.32-$0.25-$1.01 - $0.53-28.00%MissN/A15N/AMay 5, 2021$111.61M
    Dec 31, 2020$0.44$0.28$0.05 - $0.50+57.14%Beat-68.8%16N/AFeb 24, 2021$290.28M
    Sep 30, 2020-$0.22-$0.16-$0.32 - $0.43-37.50%Miss-222.2%17N/ANov 4, 2020$160.08M
    Jun 30, 2020-$0.23-$0.28-$0.48 - -$0.07+17.86%BeatN/A18N/AAug 5, 2020$145.54M
    Mar 31, 2020-$0.35-$0.11-$0.40 - $0.18-218.18%Miss-156.5%18N/AMay 6, 2020$133.37M
    Dec 31, 2019$1.41$0.93$0.19 - $1.32+51.61%Beat+642.1%18N/AFeb 26, 2020$493.68M
    Sep 30, 2019$0.18-$0.32-$0.59 - -$0.17+156.25%BeatN/A14N/ANov 6, 2019$167.89M
    Jun 30, 2019-$0.01-$0.20-$0.50 - -$0.05+95.00%BeatN/A15N/AAug 7, 2019$163.81M
    Mar 31, 2019$0.62$0.78-$0.39 - $1.18-20.51%MissN/A14N/AMay 9, 2019$297.21M
    Dec 31, 2018$0.19-$0.05-$0.27 - $0.23+480.00%Beat+850.0%13N/AFeb 27, 2019$192.11M
    Sep 30, 2018-$0.03-$0.17-$0.47 - $0.10+82.35%BeatN/A11N/ANov 6, 2018$145.40M
    Jun 30, 2018-$0.29-$0.19-$0.45 - $0.50-52.63%MissN/A11N/AAug 7, 2018$117.75M
    Mar 31, 2018-$0.01-$0.15-$0.42 - $0.94+93.33%Beat-133.3%10N/AMay 4, 2018$144.42M
    Dec 31, 2017$0.02$0.01-$0.50 - $0.51+100.00%Beat-91.7%12N/AFeb 27, 2018$167.79M
    Sep 30, 2017$0.00-$0.08-$0.21 - $0.33+95.75%Beat-105.7%12N/ANov 7, 2017$118.31M
    Jun 30, 2017-$0.09-$0.06-$0.57 - $0.19-50.00%MissN/A9N/AAug 8, 2017$112.27M
    Mar 31, 2017$0.03-$0.31N/A+109.68%BeatN/AN/AN/AMay 9, 2017$115.80M
    Dec 31, 2016$0.24-$0.12N/A+300.00%BeatN/AN/AN/AFeb 28, 2017$186.50M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$1.83, after -$2.39 the year before. It was -$0.69 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$1.83N/A
    Dec 31, 2024-$2.39N/A
    Dec 31, 2023-$2.00N/A
    Dec 31, 2022-$2.35-579.6%
    Dec 31, 2021$0.49N/A
    Dec 31, 2020-$0.36-116.4%
    Dec 31, 2019$2.20N/A
    Dec 31, 2018-$0.14N/A
    Dec 31, 2017-$0.04N/A
    Dec 31, 2016-$0.69N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,300 words across 18 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20268,30818
    2026Q2Jun 30, 20268,55718
    2026Q1Mar 31, 20266,66218
    2025Q4Dec 31, 20257,74617
    2025Q3Sep 30, 20257,63616
    2025Q2Jun 30, 20258,36217
    2025Q1Mar 31, 20258,04217
    2024Q4Dec 31, 20249,12117

    2026Q3 Earnings Call

    Opening remarks

    Wade Walke Senior Vice President of Investor Relations Thank you, Chris. Before we begin, I encourage everyone to go to the Investors section of the Ionis website to view the press release and related financial tables we will be discussing today, including a reconciliation of GAAP to non-GAAP financials. We believe non-GAAP financial results better represent the economics of our business and how we manage our business. We've also posted slides on our website that accompany today's call. With me this morning are Brett Monia, Chief Executive Officer; Kyle Jenne, Chief Global Product Strategy Officer; Holly Kordasiewicz, Chief Development Officer; and Beth Hougen, Chief Financial Officer. I would like to draw your attention to Slide 3, which contains our forward-looking language statement. During this call, we will be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. As a result, you are cautioned not to rely on these forward-looking statements. I encourage you to consult the risk factors contained in our SEC filings for additional detail. And with that, I'll turn the call over to Brett.

    Brett Monia CEO Thanks, Wade. Good morning, everyone, and thank you for joining us on today's call. Through the first 3 quarters of 2026, Ionis has continued to evolve and grow as a commercial-stage biotechnology company, achieving numerous important milestones. In addition to TRYNGOLZA for FCS and DAWNZERA for HAE, our Ionis-owned commercial portfolio now includes TRYNGOLZA for severe hypertriglyceridemia, or sHTG, our first launch in a large patient population, and ZANVASTRO, our first independent launch in neurology. Although 2 recent Phase III readouts did not deliver the outcomes we hoped for, we have achieved a number of other important firsts for patients across our business that position us for further growth. This includes the approval of HIBSAGO for chronic hepatitis B virus in the U.S. and Japan and positive Phase III results for sefaxersen in IgA nephropathy and ulefnersen in FUS-ALS. Our substantial progress keeps us on track to achieve our full-year 2026 total revenue, operating loss, and cash guidance, and DAWNZERA's continued positive momentum supports our confidence in achieving its 2026 product sales guidance. For TRYNGOLZA, we are lowering our 2026 full-year revenue guidance to approximately $50 million to reflect a more gradual launch ramp than we had anticipated. As the first and only treatment approved to reduce triglycerides and the risk of acute pancreatitis in people living with sHTG, TRYNGOLZA requires HCPs to adopt a new approach to patient care, which takes time. In these early days, we are encouraged by the fundamentals underlying the launch, including strong physician enthusiasm. We are refining our launch tactics to translate this enthusiasm into action.

    Frequently Asked Questions About IONS

    When is Ionis Pharmaceuticals's next earnings date?

    Ionis Pharmaceuticals's next earnings report is expected for Feb 23, 2027.

    Did IONS beat earnings estimates last quarter?

    Yes. Ionis Pharmaceuticals reported EPS of -$0.66 for the quarter ended Sep 30, 2026, above the -$1.22 estimate, a 45.90% surprise.

    What EPS do analysts expect from IONS next quarter?

    The consensus EPS estimate for Ionis Pharmaceuticals for the quarter ending Dec 31, 2026 is -$1.50 from 25 analysts, with estimates from -$1.71 to -$1.31.

    How often does IONS beat earnings estimates?

    Ionis Pharmaceuticals beat the EPS estimate in each of the last 15 quarters, with an average surprise of +62.15%.